The Interactive Effect of GHR-Exon 3 and -202 A/C IGFBP3 Polymorphisms on rhGH Responsiveness and Treatment Outcomes in Patients with Turner Syndrome

Show simple item record

dc.contributor Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP BRAZ, Adriana F. FMUSP-HC
RAMOS, Ester S.
JORGE, Alexander A. L. FMUSP-HC 2012
dc.identifier.citation JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, v.97, n.4, p.E671-E677, 2012
dc.identifier.issn 0021-972X
dc.description.abstract Context: There is great interindividual variability in the response to recombinant human (rh) GH therapy in patients with Turner syndrome (TS). Ascertaining genetic factors can improve the accuracy of growth response predictions. Objective: The objective of the study was to assess the individual and combined influence of GHR-exon 3 and -202 A/C IGFBP3 polymorphisms on the short-and long-term outcomes of rhGH therapy in patients with TS. Design and Patients: GHR-exon 3 and -202 A/C IGFBP3 genotyping (rs2854744) was correlated with height data of 112 patients with TS who remained prepubertal during the first year of rhGH therapy and 65 patients who reached adult height after 5 +/- 2.5 yr of rhGH treatment. Main Outcome Measures: First-year growth velocity and adult height were measured. Results: Patients carrying at least one GHR-d3 or -202 A-IGFBP3 allele presented higher mean first-year growth velocity and achieved taller adult heights than those homozygous for GHR-fl or -202 C-IGFBP3 alleles, respectively. The combined analysis of GHR-exon 3 and -202 A/C IGFBP3 genotypes showed a clear nonadditive epistatic influence on adult height of patients with TS treated with rhGH (GHR-exon 3 alone, R-2 = 0.27; -202 A/C IGFBP3, R-2 = 0.24; the combined genotypes, R-2 = 0.37 at multiple linear regression). Together with clinical factors, these genotypes accounted for 61% of the variability in adult height of patients with TS after rhGH therapy. Conclusion: Homozygosity for the GHR-exon3 full-length allele and/or the -202C-IGFBP3 allele are associated with less favorable short-and long-term growth outcomes after rhGH treatment in patients with TS.
dc.description.sponsorship · Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [05/04726-0, 05/50144-2]
· Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) [301339/2008-9, 300938/2006-3, 475870/2009-3, 301477/2009-4]
dc.language.iso eng
dc.publisher ENDOCRINE SOC
dc.relation.ispartof Journal of Clinical Endocrinology & Metabolism
dc.rights openAccess
dc.subject.other factor-binding protein-3; growth-hormone treatment; for-gestational-age; receptor polymorphism; promoter polymorphism; serum-levels; gh-receptor; children; height; girls
dc.title The Interactive Effect of GHR-Exon 3 and -202 A/C IGFBP3 Polymorphisms on rhGH Responsiveness and Treatment Outcomes in Patients with Turner Syndrome
dc.type article
dc.rights.holder Copyright ENDOCRINE SOC LIM/42 LIM/25
dc.identifier.doi 10.1210/jc.2011-2521
dc.identifier.pmid 22278433
dc.type.category original article
dc.type.version publishedVersion BRAZ, Adriana F.:FM: COSTALONGA, Everlayny F.:FM: MONTENEGRO, Luciana R.:FM:MCM TRARBACH, Ericka B.:FM:MCM MALAQUIAS, Alexsandra C.:FM: MENDONCA, Berenice B.:FM:MCM ARNHOLD, Ivo J. P.:HC:ICHC JORGE, Alexander A. L.:FM:MCM · ANTONINI, Sonir R. R.:Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Pediat, BR-05508 Sao Paulo, Brazil
· RAMOS, Ester S.:Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Genet, BR-14040900 Sao Paulo, Brazil 2-s2.0-84859527174 WOS:000302787800024 CHEVY CHASE USA
hcfmusp.relation.reference · Alvarez-Nava F, 2010, J PEDIATR ENDOCR MET, V23, P773, DOI 10.1515/jpem.2010.127
· Audi L, 2006, J CLIN ENDOCR METAB, V91, P5038, DOI 10.1210/jc.2006-0828
· Bannink EMN, 2006, CLIN ENDOCRINOL, V65, P310, DOI 10.1111/j.1365-2265.2006.02594.x
· Baxter RC, 2000, AM J PHYSIOL-ENDOC M, V278, pE967
· Binder G, 2006, J CLIN ENDOCR METAB, V91, P659, DOI 10.1210/jc.2005-1581
· Binder G, 2008, CLIN ENDOCRINOL, V68, P567, DOI 10.1111/j.1365-2265.2007.03090.x
· Bondy CA, 2007, J CLIN ENDOCR METAB, V92, P10, DOI 10.1210/jc.2006-1374
· Clement-Jones M, 2000, HUM MOL GENET, V9, P695, DOI 10.1093/hmg/9.5.695
· Costalonga EF, 2011, PHARMACOGENOMIC 0405, DOI [10.1038/tpj.2011.13, DOI 10.1038/TPJ.2011.13]
· Costalonga EF, 2009, J CLIN ENDOCR METAB, V94, P588, DOI 10.1210/jc.2008-1608
· Deal C, 2001, J CLIN ENDOCR METAB, V86, P1274, DOI 10.1210/jc.86.3.1274
· Dos Santos C, 2004, NAT GENET, V36, P720, DOI 10.1038/ng1379
· Geffner ME, 2007, HORM RES, V68, P51, DOI 10.1159/000110476
· Grimberg A, 2000, J CELL PHYSIOL, V183, P1, DOI 10.1002/(SICI)1097-4652(200004)183:1<1::AID-JCP1>3.0.CO;2-J
· Jogie-Brahim S, 2009, ENDOCR REV, V30, P417, DOI 10.1210/er.2008-0028
· Jorge AAL, 2009, HORM RES, V71, P55, DOI 10.1159/000192438
· Ko JM, 2010, CLIN ENDOCRINOL, V72, P196, DOI 10.1111/j.1365-2265.2009.03681.x
· Kuczmarski R J, 2000, Adv Data, P1
· Meyer S, 2009, PHARMACOGENOMICS, V10, P1599, DOI [10.2217/pgs.09.91, 10.2217/PGS.09.91]
· Mohan S, 2002, J ENDOCRINOL, V175, P19, DOI 10.1677/joe.0.1750019
· Mullis PE, 2011, BEST PRACT RES CL EN, V25, P25, DOI 10.1016/j.beem.2010.06.006
· Pantel J, 2000, J BIOL CHEM, V275, P18664, DOI 10.1074/jbc.M001615200
· Ranke MB, 2007, PEDIATR RES, V61, P105, DOI 10.1203/01.pdr.0000250039.42000.c9
· Ross JL, 2011, NEW ENGL J MED, V364, P1230, DOI 10.1056/NEJMoa1005669
· Stephure DK, 2005, J CLIN ENDOCR METAB, V90, P3360, DOI 10.1210/jc.2004-2187
· TANNER JM, 1966, ARCH DIS CHILD, V41, P454
· van der Kaay DCM, 2009, GROWTH HORM IGF RES, V19, P198, DOI 10.1016/j.ghir.2008.08.010
· van Pareren YK, 2003, J CLIN ENDOCR METAB, V88, P1119, DOI 10.1210/jc.2002-021171
· Wassenaar MJE, 2009, J CLIN ENDOCR METAB, V94, P3721, DOI 10.1210/jc.2009-0425
dc.description.index MEDLINE
hcfmusp.citation.scopus 7
hcfmusp.citation.wos 6

Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace


My Account